506 - Week 26 Interim Analysis of Implementation and Delivery of Long-Acting Injectable Cabotegravir for PrEP in a Community Pharmacy Setting

Saturday, October 19, 2024

11:00 AM – 11:15 AM US PT

Location: 411

Presenting Author(s)

Elyse Tung, PharmD, BCACP (she/her/hers)

Director of Clinical Services
Kelley-Ross Pharmacy
Seattle, WA, United States

Slides

Co-Author(s)

AD

Alexi Duenas, PharmD

Clinical Pharmacist
Kelley-Ross Pharmacy
Seattle, Washington, United States
PS

Peter Shalit, MD, PhD

HIV Specialist
Seattle, WA, United States

Disclosure(s):

Elyse Tung, PharmD, BCACP: Gilead Sciences Inc.: Advisor/Consultant, Honoraria; National HIV PrEP Curriculum: Advisor/Consultant; Viiv Healthcare Ltd.: Advisor/Consultant

Alexi Duenas, PharmD: No financial relationships to disclose

Peter Shalit, MD, PhD: Gilead Sciences: Grant/Research Support, Honoraria; ViiV Healthcare: Advisor/Consultant, Grant/Research Support, Honoraria